$EVFM
Evofem Biosciences, Inc. Stock $evfm

$evfm Overview Financials Valuation SEC Filings Company Website

2024 Q3 Form 10-Q Financial Statement

#000149315224031846 Filed on August 14, 2024

Income Statement

Concept	2024 Q3	2024 Q2	2023 Q2
Revenue	$4.496M	$4.160M	$2.458M
YoY Change	-12.05%	69.24%	-59.26%
Cost Of Revenue	$869.0K	$769.0K	$2.293M
YoY Change	-54.0%	-66.46%	78.44%
Gross Profit	$3.627M	$3.391M	$165.0K
YoY Change	12.53%	1955.15%	-96.53%
Gross Profit Margin	80.67%	81.51%	6.71%
Selling, General & Admin	$5.434M	$4.510M	$7.099M
YoY Change	-11.8%	-36.47%	-66.86%
% of Gross Profit	149.82%	133.0%	4302.42%
Research & Development	$332.0K	$270.0K	$402.0K
YoY Change	-45.93%	-32.84%	-94.81%
% of Gross Profit	9.15%	7.96%	243.64%
Depreciation & Amortization		$7.000K	$173.0K
YoY Change		-95.95%	-30.8%
% of Gross Profit		0.21%	104.85%
Operating Expenses	$5.766M	$4.780M	$7.501M
YoY Change	-14.89%	-36.28%	-74.28%
Operating Profit	-$2.440M	-$1.389M	-$7.336M
YoY Change	-31.31%	-81.07%	-69.96%
Interest Expense		$3.306M	-$92.00K
YoY Change		-3693.48%	-99.91%
% of Operating Profit
Other Income/Expense, Net	$67.00K	$2.748M	-$1.219M
YoY Change	-99.9%	-325.43%	-98.8%
Pretax Income	-$2.373M	$1.359M	-$8.555M
YoY Change	-103.59%	-115.89%	-93.21%
Income Tax	-$8.000K	$8.000K	$3.000K
% Of Pretax Income		0.59%
Net Earnings	-$2.365M	$1.351M	-$8.558M
YoY Change	-103.58%	-115.79%	-93.21%
Net Earnings / Revenue	-52.6%	32.48%	-348.17%
Basic Earnings Per Share	-$0.02	$0.02	-$5.43
Diluted Earnings Per Share	-$0.02	$0.00	-$5.43
COMMON SHARES
Basic Shares Outstanding	100.3M shares	62.06M shares	216.0M shares
Diluted Shares Outstanding	96.46M shares	1.614B shares	1.576M shares

Balance Sheet

Concept	2024 Q3	2024 Q2	2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments		$0.00	$0.00
YoY Change			-100.0%
Cash & Equivalents
Short-Term Investments
Other Short-Term Assets		$1.537M	$3.144M
YoY Change		-51.11%	-64.16%
Inventory	$1.463M	$1.060M	$3.674M
Prepaid Expenses
Receivables	$5.393M	$4.617M	$5.198M
Other Receivables		$0.00	$0.00
Total Short-Term Assets	$8.577M	$7.214M	$12.02M
YoY Change	-25.45%	-39.96%	-71.33%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.181M	$1.187M	$1.668M
YoY Change	-27.59%	-28.84%	-68.56%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$36.00K	$36.00K	$195.0K
YoY Change	2.86%	-81.54%	-84.07%
Total Long-Term Assets	$15.37M	$1.337M	$2.058M
YoY Change	745.62%	-35.03%	-82.21%
TOTAL ASSETS
Total Short-Term Assets	$8.577M	$7.214M	$12.02M
Total Long-Term Assets	$15.37M	$1.337M	$2.058M
Total Assets	$23.94M	$8.551M	$14.07M
YoY Change	79.72%	-39.24%	-73.68%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$16.86M	$16.03M	$17.15M
YoY Change	4.11%	-6.52%	11.46%
Accrued Expenses	$5.124M	$4.752M	$4.216M
YoY Change	0.47%	12.71%	-39.06%
Deferred Revenue	$4.500M	$3.600M
YoY Change
Short-Term Debt	$268.0K	$397.0K	$0.00
YoY Change			-100.0%
Long-Term Debt Due		$42.89M	$43.00M
YoY Change		-0.27%	-62.76%
Total Short-Term Liabilities	$76.29M	$73.18M	$69.72M
YoY Change	12.4%	4.97%	-73.75%
LONG-TERM LIABILITIES
Long-Term Debt		$0.00	$0.00
YoY Change
Other Long-Term Liabilities		$1.000K	$22.00K
YoY Change		-95.45%	-99.44%
Total Long-Term Liabilities		$1.000K	$22.00K
YoY Change		-95.45%	-99.44%
TOTAL LIABILITIES
Total Short-Term Liabilities	$76.29M	$73.18M	$69.72M
Total Long-Term Liabilities		$1.000K	$22.00K
Total Liabilities	$90.07M	$73.18M	$69.74M
YoY Change	32.69%	4.93%	-74.12%
SHAREHOLDERS EQUITY
Retained Earnings	-$894.6M	-$892.3M	-$949.6M
YoY Change	1.13%	-6.03%	-5.04%
Common Stock	$10.00K	$8.000K	$0.00
YoY Change			-100.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$70.89M	-$69.32M	-$55.66M
YoY Change
Total Liabilities & Shareholders Equity	$23.94M	$8.551M	$14.07M
YoY Change	79.72%	-39.24%	-73.68%

Cashflow Statement

Concept	2024 Q3	2024 Q2	2023 Q2
OPERATING ACTIVITIES
Net Income	-$2.365M	$1.351M	-$8.558M
YoY Change	-103.58%	-115.79%	-93.21%
Depreciation, Depletion And Amortization		$7.000K	$173.0K
YoY Change		-95.95%	-30.8%
Cash From Operating Activities		-$1.141M	-$1.494M
YoY Change		-23.63%	-94.4%
INVESTING ACTIVITIES
Capital Expenditures		$0.00	$1.000K
YoY Change		-100.0%	-100.59%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities		$0.00	-$1.000K
YoY Change		-100.0%	-99.41%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		1.144M	597.0K
YoY Change		91.62%	-98.56%
NET CHANGE
Cash From Operating Activities		-1.141M	-1.494M
Cash From Investing Activities		0.000	-1.000K
Cash From Financing Activities		1.144M	597.0K
Net Change In Cash		3.000K	-898.0K
YoY Change		-100.33%	-106.18%
FREE CASH FLOW
Cash From Operating Activities		-$1.141M	-$1.494M
Capital Expenditures		$0.00	$1.000K
Free Cash Flow		-$1.141M	-$1.495M
YoY Change		-23.68%	-94.36%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Entity Central Index Key EntityCentralIndexKey	0001618835
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	20-8527075
	dei	Entity Address Address Line1 EntityAddressAddressLine1	7770 Regents Road
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 113-618
	dei	Entity Address City Or Town EntityAddressCityOrTown	San Diego
	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8520000	usd
CY2024Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue		usd
CY2024Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	100328686	shares
CY2024Q2	us-gaap	Restricted Cash Current RestrictedCashCurrent	692000	usd
CY2024Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	4617000	usd
CY2024Q2	us-gaap	Inventory Net InventoryNet	1060000	usd
CY2024Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	845000	usd
CY2024Q2	us-gaap	Assets Current AssetsCurrent	7214000	usd
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1187000	usd
CY2024Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	114000	usd
CY2024Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	36000	usd
CY2024Q2	us-gaap	Assets Assets	8551000	usd
CY2023Q4	us-gaap	Assets Assets	10554000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	17020000	usd
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q4	us-gaap	Short Term Borrowings ShortTermBorrowings		usd
CY2023Q4	EVFM	Other Liabilities Current Related Party OtherLiabilitiesCurrentRelatedParty		usd
CY2024Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2024Q2	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2024Q2	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2023Q2	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
CY2023Q2	EVFM	Convertible Preferred Deemed Dividends ConvertiblePreferredDeemedDividends		usd
	EVFM	Convertible Preferred Deemed Dividends ConvertiblePreferredDeemedDividends		usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt		usd
	us-gaap	Gain Loss On Termination Of Lease GainLossOnTerminationOfLease		usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises		usd
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt		usd
	EVFM	Proceeds From Reinstatement Of Merger Agreement Related Party ProceedsFromReinstatementOfMergerAgreementRelatedParty		usd
	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt		usd
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt		usd
	EVFM	Series E1 Shares Dividends SeriesE1SharesDividends		usd
	EVFM	Issuance Of Common Stock Upon Conversion Of Notes IssuanceOfCommonStockUponConversionOfNotes		usd
	EVFM	Issuance Of Common Stock Upon Exercise Of Warrants IssuanceOfCommonStockUponExerciseOfWarrants		usd
	EVFM	Purchases Of Property And Equipment Included In Accounts Payable And Accrued Expenses PurchasesOfPropertyAndEquipmentIncludedInAccountsPayableAndAccruedExpenses		usd
CY2024Q2	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2024-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-36754
	dei	Entity Registrant Name EntityRegistrantName	EVOFEM BIOSCIENCES, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92122
	dei	City Area Code CityAreaCode	(858)
	dei	Local Phone Number LocalPhoneNumber	550-1900
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001 per share
	dei	Trading Symbol TradingSymbol	EVFM
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
	dei	Entity Listing Par Value Per Share EntityListingParValuePerShare	0.0001
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	35000	usd
CY2024Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	16033000	usd
CY2024Q2	us-gaap	Short Term Borrowings ShortTermBorrowings	397000	usd
CY2024Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4752000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4227000	usd
CY2024Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3280000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2609000	usd
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	113000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	97000	usd
CY2024Q2	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	942000	usd
CY2023Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	1926000	usd
CY2024Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	3776000	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	3316000	usd
CY2024Q2	EVFM	Other Liabilities Current Related Party OtherLiabilitiesCurrentRelatedParty	1000000	usd
CY2024Q2	us-gaap	Liabilities Current LiabilitiesCurrent	73178000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	72463000	usd
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	8000	usd
CY2024Q2	us-gaap	Liabilities Liabilities	73179000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	72471000	usd
CY2024Q2	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Temporary Equity Par Or Stated Value Per Share TemporaryEquityParOrStatedValuePerShare	0.0001
CY2024Q2	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	4687000	usd
CY2023Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	4593000	usd
CY2024Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2024Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2024Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2024Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	3000000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	3000000000	shares
CY2024Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	82828686	shares
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	82828686	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	20007799	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	20007799	shares
CY2024Q2	us-gaap	Common Stock Value CommonStockValue	8000	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	2000	usd
CY2024Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	823709000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	823036000	usd
CY2024Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-781000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-849000	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-892251000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-888699000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	-69315000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-66510000	usd
CY2024Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	8551000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	10554000	usd
CY2024Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	4160000	usd
CY2023Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2458000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7763000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	8267000	usd
CY2024Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	769000	usd
CY2023Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	2293000	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1453000	usd
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	3669000	usd
CY2024Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	270000	usd
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	402000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	864000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	942000	usd
CY2024Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	2243000	usd
CY2023Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	2197000	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	4588000	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	6051000	usd
CY2024Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2267000	usd
CY2023Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4902000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5091000	usd
CY2024Q2	us-gaap	Costs And Expenses CostsAndExpenses	5549000	usd
CY2023Q2	us-gaap	Costs And Expenses CostsAndExpenses	9794000	usd
	us-gaap	Costs And Expenses CostsAndExpenses	11996000	usd
	us-gaap	Costs And Expenses CostsAndExpenses	19182000	usd
CY2024Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-1389000	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-7336000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-4233000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-10915000	usd
CY2024Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	6000	usd
CY2023Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	8000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	10000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	26000	usd
CY2024Q2	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	558000	usd
CY2023Q2	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	1127000	usd
	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	1174000	usd
	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	1445000	usd
CY2024Q2	us-gaap	Gain Loss On Sale Of Derivatives GainLossOnSaleOfDerivatives	-25000	usd
CY2023Q2	us-gaap	Gain Loss On Sale Of Derivatives GainLossOnSaleOfDerivatives	-27000	usd
	us-gaap	Gain Loss On Sale Of Derivatives GainLossOnSaleOfDerivatives	-3300000	usd
	us-gaap	Gain Loss On Sale Of Derivatives GainLossOnSaleOfDerivatives	-111000	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	1120000	usd
CY2024Q2	EVFM	Change In Fair Value Of Financial Instruments ChangeInFairValueOfFinancialInstruments	3325000	usd
CY2023Q2	EVFM	Change In Fair Value Of Financial Instruments ChangeInFairValueOfFinancialInstruments	-73000	usd
	EVFM	Change In Fair Value Of Financial Instruments ChangeInFairValueOfFinancialInstruments	4127000	usd
	EVFM	Change In Fair Value Of Financial Instruments ChangeInFairValueOfFinancialInstruments	1539000	usd
CY2024Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	2748000	usd
CY2023Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1219000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	783000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	9000	usd
CY2024Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	1359000	usd
CY2023Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-8555000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3450000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-10906000	usd
CY2024Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	8000	usd
CY2023Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	8000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	6000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	1351000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-8558000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3458000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-10912000	usd
CY2024Q2	EVFM	Convertible Preferred Deemed Dividends ConvertiblePreferredDeemedDividends	-47000	usd
	EVFM	Convertible Preferred Deemed Dividends ConvertiblePreferredDeemedDividends	-94000	usd
CY2024Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	1304000	usd
CY2023Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-8558000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-3552000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-10912000	usd
CY2024Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.02
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-5.43
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.07
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-6.60
CY2024Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.00
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-5.43
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.07
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-6.60
CY2024Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	66773313	shares
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1576158	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	48983853	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1654026	shares
CY2024Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1613722212	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1576158	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	48983853	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1654026	shares
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	1351000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-8558000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3458000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-10912000	usd
CY2024Q2	us-gaap	Other Comprehensive Income Loss Financial Liability Fair Value Option After Tax And Reclassification Adjustment OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustment	-256000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Financial Liability Fair Value Option After Tax And Reclassification Adjustment OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustment	8368000	usd
	us-gaap	Other Comprehensive Income Loss Financial Liability Fair Value Option After Tax And Reclassification Adjustment OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustment	68000	usd
	us-gaap	Other Comprehensive Income Loss Financial Liability Fair Value Option After Tax And Reclassification Adjustment OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustment	23828000	usd
CY2024Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	1095000	usd
CY2023Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-190000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3390000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	12916000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-66510000	usd
CY2024Q1	EVFM	Stock Issued During Period Value Common Stock Upon Cash Exercise Of Warrants StockIssuedDuringPeriodValueCommonStockUponCashExerciseOfWarrants	15000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	89000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	35000	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	237000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Loss Financial Liability Fair Value Option After Tax And Reclassification Adjustment OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustment	324000	usd
CY2024Q1	EVFM	Adjustments To Additional Paid In Capital Value Accumulated Deficit And Retained Earnings AdjustmentsToAdditionalPaidInCapitalValueAccumulatedDeficitAndRetainedEarnings	-47000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-4809000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	-70666000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	-70666000	usd
CY2024Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	68000	usd
CY2024Q2	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	16000	usd
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	219000	usd
CY2024Q2	us-gaap	Other Comprehensive Income Loss Financial Liability Fair Value Option After Tax And Reclassification Adjustment OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustment	-256000	usd
CY2024Q2	EVFM	Adjustments To Additional Paid In Capital Value Accumulated Deficit And Retained Earnings AdjustmentsToAdditionalPaidInCapitalValueAccumulatedDeficitAndRetainedEarnings	-47000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	1351000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	-69315000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	-69315000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-71800000	usd
CY2023Q1	EVFM	Stock Issued During Period Value Common Stock Upon Cash Exercise Of Warrants StockIssuedDuringPeriodValueCommonStockUponCashExerciseOfWarrants	67000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	180000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt	1629000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Financial Liability Fair Value Option After Tax And Reclassification Adjustment OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustment	15460000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	417000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-2354000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-56401000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-56401000	usd
CY2023Q2	EVFM	Stock Issued During Period Value Common Stock Upon Cash Exercise Of Warrants StockIssuedDuringPeriodValueCommonStockUponCashExerciseOfWarrants	101000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	6000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	6000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	53000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt	499000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	268000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Financial Liability Fair Value Option After Tax And Reclassification Adjustment OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustment	8368000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-8558000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-8558000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-55664000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-55664000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-3458000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-10912000	usd
	us-gaap	Gain Loss On Sale Of Derivatives GainLossOnSaleOfDerivatives	-3300000	usd
	us-gaap	Gain Loss On Sale Of Derivatives GainLossOnSaleOfDerivatives	-111000	usd
	EVFM	Change In Fair Value Of Financial Instruments ChangeInFairValueOfFinancialInstruments	4127000	usd
	EVFM	Change In Fair Value Of Financial Instruments ChangeInFairValueOfFinancialInstruments	1539000	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	1120000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	456000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	685000	usd
	us-gaap	Depreciation Depreciation	19000	usd
	us-gaap	Depreciation Depreciation	418000	usd
	us-gaap	Interest Expense InterestExpense	1109000	usd
	us-gaap	Interest Expense InterestExpense	1134000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	82000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	1208000	usd
	us-gaap	Gain Loss On Termination Of Lease GainLossOnTerminationOfLease	459000	usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-11000	usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-1858000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1121000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	4072000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-637000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-1705000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-349000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-2435000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-987000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2167000	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	1000000	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	840000	usd
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	671000	usd
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-625000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-81000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-1388000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1018000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6434000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	14000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-14000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-4000	usd
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	160000	usd
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	2138000	usd
	EVFM	Proceeds From Reinstatement Of Merger Agreement Related Party ProceedsFromReinstatementOfMergerAgreementRelatedParty	1000000	usd
	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	397000	usd
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	253000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1144000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2298000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	112000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-4140000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	580000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	4776000	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	692000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	636000	usd
	EVFM	Issuance Of Common Stock Upon Exercise Of Purchase Rights IssuanceOfCommonStockUponExerciseOfPurchaseRights	-157000	usd
	EVFM	Issuance Of Common Stock Upon Exercise Of Purchase Rights IssuanceOfCommonStockUponExerciseOfPurchaseRights	-186000	usd
	EVFM	Series E1 Shares Dividends SeriesE1SharesDividends	94000	usd
	EVFM	Issuance Of Common Stock Upon Conversion Of Notes IssuanceOfCommonStockUponConversionOfNotes	-51000	usd
	EVFM	Issuance Of Common Stock Upon Exercise Of Warrants IssuanceOfCommonStockUponExerciseOfWarrants	15000	usd
	EVFM	Purchases Of Property And Equipment Included In Accounts Payable And Accrued Expenses PurchasesOfPropertyAndEquipmentIncludedInAccountsPayableAndAccruedExpenses	78000	usd
CY2024Q2	EVFM	Working Capital Surplus Deficit WorkingCapitalSurplusDeficit	66000000.0	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-892300000	usd
CY2022Q4	us-gaap	Share Price SharePrice	0.01
CY2022Q4	us-gaap	Share Price SharePrice	0.01
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84B_eus-gaap--UseOfEstimates_zs6iqj2GHsX6" style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_866_zkrPaPrZ0i44">Use of Estimates</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and the notes thereto.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant estimates affecting amounts reported or disclosed in the condensed consolidated financial statements include, but are not limited to: the assumptions used in measuring the revenue gross-to-net variable consideration items; the trade accounts receivable credit loss reserve estimate; the assumptions used in estimating the fair value of convertible notes, preferred stock, warrants and purchase rights issued; the assumptions used in the valuation of inventory; the useful lives of property and equipment; the recoverability of long-lived assets; and the valuation of deferred tax assets. These assumptions are more fully described in <a href="#am_012">Note 3 – Revenue</a>, <a href="#am_013">Note 4 – Debt</a>, <a href="#MS_002">Note 6 - Fair Value of Financial Instruments</a>, <a href="#MS_003">Note 7 - Commitments and Contingencies</a>, and <a href="#p_010">Note 9 - Stock-based Compensation</a>. The Company bases its estimates on historical experience and other market-specific or other relevant assumptions that it believes to be reasonable under the circumstances and adjusts when facts and circumstances dictate. The estimates are the basis for making judgments about the carrying values of assets, liabilities and recorded expenses that are not readily apparent from other sources. As future events and their effects cannot be determined with precision, actual results may materially differ from those estimates or assumptions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_847_eus-gaap--ConcentrationRiskCreditRisk_z2G3H4fGb9rl" style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span id="xdx_861_z6Bgi2pSdtae">Concentrations of Credit Risk</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and restricted cash. Deposits in the Company’s checking, time deposit and investment accounts are maintained in federally insured financial institutions and are subject to federally insured limits or limits set by Securities Investor Protection Corporation. The Company invests in funds through a major U.S. bank and is exposed to credit risk in the event of default to the extent of amounts recorded on the condensed consolidated balance sheets.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has not experienced any losses in such accounts and believes it is not exposed to significant concentrations of credit risk on its cash, cash equivalents and restricted cash balances on amounts in excess of federally insured limits due to the financial position of the depository institutions in which these deposits are held.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is also subject to credit risk related to its trade accounts receivable from product sales. Its customers are located in the U.S. and consist of wholesale distributors, retail pharmacies, and mail-order specialty pharmacies. The Company extends credit to its customers in the normal course of business after evaluating their overall financial condition and evaluates the collectability of its accounts receivable by periodically reviewing the age of the receivables, the financial condition of its customers, and its past collection experience. Historically, the Company has not experienced any credit losses. As of June 30, 2024, based on the evaluation of these factors the Company did not record a reserve for expected credit loss.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Products are distributed primarily through three major distributors and mail-order pharmacies, who receive service fees calculated as a percentage of the gross sales, and a fee-per-unit shipped, respectively. These entities are not obligated to purchase any set number of units. They distribute products on demand as orders are received.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the three and six months ended June 30, 2024, the Company’s three largest customers combined made up approximately <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240401__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--ThreeLargestCustomersCombinedMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zS5lQv0lW5Ek">75</span>% and <span id="xdx_905_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--ThreeLargestCustomersCombinedMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zRAJjN2zYQPc">79</span>% of its gross product sales, respectively. For the three and six months ended June 30, 2023, the Company’s three largest customers combined made up approximately <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230401__20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--ThreeLargestCustomersCombinedMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zuQeJeqgPFa8" title="Concentration risk percentage">81</span>% and <span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__srt--MajorCustomersAxis__custom--ThreeLargestCustomersCombinedMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zONPE7EUacSb">84</span>% of its gross product sales, respectively. As of June 30, 2024 and December 31, 2023, the Company’s three largest customers combined made up <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--FourLargestCustomersCombinedMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zckrONokq1mh">82</span>% and <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--FourLargestCustomersCombinedMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zSRgu1by2Ftc" title="Concentration risk percentage">87</span>%, respectively, of its trade accounts receivable balance.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	25000000.0	usd
CY2024Q2	us-gaap	Warrant Down Round Feature Decrease In Net Income Loss To Common Shareholder Amount WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount	0	usd
	us-gaap	Warrant Down Round Feature Decrease In Net Income Loss To Common Shareholder Amount WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount	0	usd
CY2023Q2	us-gaap	Warrant Down Round Feature Decrease In Net Income Loss To Common Shareholder Amount WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount	0	usd
	us-gaap	Warrant Down Round Feature Decrease In Net Income Loss To Common Shareholder Amount WarrantDownRoundFeatureDecreaseInNetIncomeLossToCommonShareholderAmount	0	usd
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5671114941	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	191005656	shares
CY2024Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	1304000	usd
CY2024Q2	EVFM	Purchase Rights Change In Fair Value PurchaseRightsChangeInFairValue	-3300000	usd
CY2024Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-1996000	usd
CY2024Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	66773313	shares
CY2024Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1613722212	shares
CY2024Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.00
CY2024Q2	EVFM	Product Revenue Variable Consideration Liability Current ProductRevenueVariableConsiderationLiabilityCurrent	100000	usd
CY2023Q4	EVFM	Product Revenue Variable Consideration Liability Current ProductRevenueVariableConsiderationLiabilityCurrent	300000	usd
CY2024Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	3600000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	3200000	usd
CY2021Q4	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	50000000	usd
CY2023Q2	EVFM	Milestone Method Revenue Recognized MilestoneMethodRevenueRecognized	100000000.0	usd
CY2024Q2	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	0.0154
CY2023Q1	us-gaap	Debt Instrument Periodic Payment DebtInstrumentPeriodicPayment	92700000	usd
CY2023Q2	EVFM	Milestone Method Revenue Recognized MilestoneMethodRevenueRecognized	100000000.0	usd
CY2023Q3	EVFM	Cumulative Net Sales CumulativeNetSales	100000000	usd
CY2023Q3	EVFM	Accrued Interest Agreement Percentage AccruedInterestAgreementPercentage	0.10	pure
CY2023Q4	us-gaap	Interest Revenue Expense Net InterestRevenueExpenseNet	1000000.0	usd
CY2023Q4	us-gaap	Interest Revenue Expense Net InterestRevenueExpenseNet	1000000.0	usd
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	75300000	usd
CY2023	EVFM	Revalued Amount Extinguishment Of Debt Amount RevaluedAmountExtinguishmentOfDebtAmount	73200000	usd
CY2024Q2	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	546000	usd
CY2023Q2	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	507000	usd
	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	1081000	usd
	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	1004000	usd
CY2023Q2	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	60000	usd
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	28000	usd
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	128000	usd
CY2024Q2	us-gaap	Interest Expense Debt InterestExpenseDebt	546000	usd
CY2023Q2	us-gaap	Interest Expense Debt InterestExpenseDebt	567000	usd
	us-gaap	Interest Expense Debt InterestExpenseDebt	1109000	usd
	us-gaap	Interest Expense Debt InterestExpenseDebt	1132000	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q2	us-gaap	Inventory Raw Materials InventoryRawMaterials	430000	usd
CY2023Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	520000	usd
CY2024Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	354000	usd
CY2023Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	386000	usd
CY2024Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	276000	usd
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	791000	usd
CY2024Q2	us-gaap	Inventory Net InventoryNet	1060000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	1697000	usd
CY2024Q2	us-gaap	Inventory Adjustments InventoryAdjustments	300000	usd
CY2023Q4	us-gaap	Inventory Adjustments InventoryAdjustments	300000	usd
CY2023	us-gaap	Inventory Write Down InventoryWriteDown	1300000	usd
CY2024Q2	us-gaap	Prepaid Insurance PrepaidInsurance	488000	usd
CY2023Q4	us-gaap	Prepaid Insurance PrepaidInsurance	777000	usd
CY2024Q2	EVFM	Prepaid Research And Development Expenses PrepaidResearchAndDevelopmentExpenses	13000	usd
CY2023Q4	EVFM	Prepaid Research And Development Expenses PrepaidResearchAndDevelopmentExpenses	13000	usd
CY2024Q2	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	344000	usd
CY2023Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	405000	usd
CY2024Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	845000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1195000	usd
CY2024Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1876000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2389000	usd
CY2024Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	689000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1186000	usd
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1187000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1203000	usd
CY2023Q2	us-gaap	Depreciation Depreciation	200000	usd
	us-gaap	Depreciation Depreciation	400000	usd
CY2024Q2	EVFM	Accrued Clinical Studies Current AccruedClinicalStudiesCurrent	2498000	usd
CY2023Q4	EVFM	Accrued Clinical Studies Current AccruedClinicalStudiesCurrent	2498000	usd
CY2024Q2	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	1522000	usd
CY2023Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	1146000	usd
CY2024Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	732000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	583000	usd
CY2024Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4752000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4227000	usd
CY2024Q2	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	942000	usd
CY2023Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	1926000	usd
	EVFM	Number Of Leased Vehicles NumberOfLeasedVehicles	19	integer
CY2019Q4	EVFM	Office Square Footage OfficeSquareFootage	24474	sqft
CY2020Q2	EVFM	Office Square Footage OfficeSquareFootage	8816	sqft
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3300000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4200000	usd
CY2023Q2	us-gaap	Gain Loss On Termination Of Lease GainLossOnTerminationOfLease	200000	usd
CY2022Q2	EVFM	Lessee Operating Sublease Rentable Area LesseeOperatingSubleaseRentableArea	16637	sqft
CY2022Q2	us-gaap	Operating Lease Expense OperatingLeaseExpense	100000	usd
CY2022Q2	us-gaap	Operating Leases Of Lessor Contingent Rentals Basis Spread On Variable Rate OperatingLeasesOfLessorContingentRentalsBasisSpreadOnVariableRate	0.035	pure
CY2023Q2	us-gaap	Sublease Income SubleaseIncome	300000	usd
	us-gaap	Sublease Income SubleaseIncome	300000	usd
CY2024Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	46000	usd
CY2023Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	250000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	102000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	706000	usd
CY2024Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	219000	usd
CY2023Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	268000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	456000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	685000	usd
CY2024Q2	EVFM	Rule10b51 Arr Modified Flag Rule10b51ArrModifiedFlag	false
CY2024Q2	EVFM	Non Rule10b51 Arr Modified Flag NonRule10b51ArrModifiedFlag	false
CY2024Q2	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2024Q2	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P0Y11M1D
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P0Y9M
CY2024Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.12	pure
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.12	pure
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	66000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	55000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	121000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	7000	usd
CY2024Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	114000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	140000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	1427000	usd
CY2024Q2	us-gaap	Unrecorded Unconditional Purchase Obligation Purchases UnrecordedUnconditionalPurchaseObligationPurchases	300000	usd
	us-gaap	Unrecorded Unconditional Purchase Obligation Purchases UnrecordedUnconditionalPurchaseObligationPurchases	300000	usd
CY2023Q2	us-gaap	Unrecorded Unconditional Purchase Obligation Purchases UnrecordedUnconditionalPurchaseObligationPurchases	0	usd
	us-gaap	Unrecorded Unconditional Purchase Obligation Purchases UnrecordedUnconditionalPurchaseObligationPurchases	0	usd
CY2023Q4	us-gaap	Accounts Payable Trade Current And Noncurrent AccountsPayableTradeCurrentAndNoncurrent	2100000	usd
CY2024Q2	EVFM	Accounts Payable Trade90 Days Past Due Or More Percent AccountsPayableTrade90DaysPastDueOrMorePercent	0.92	pure
CY2022Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	894194	shares
CY2023Q4	us-gaap	Common Stock Other Shares Outstanding CommonStockOtherSharesOutstanding	9972074	shares
CY2024Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	2.42
CY2024Q2	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight	20807539000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2023Q3	us-gaap	Excess Stock Shares Authorized ExcessStockSharesAuthorized	2300	shares
CY2023Q3	EVFM	Debt Instrument Redemption Premium In Event Of Default DebtInstrumentRedemptionPremiumInEventOfDefault	0.25	pure
CY2023	us-gaap	Adjustments To Additional Paid In Capital Increase In Carrying Amount Of Redeemable Preferred Stock AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock	1800000	usd
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	3000000000	shares
CY2024Q2	EVFM	Common Stock Reserved Upon Exercise Of Stock Options Outstanding CommonStockReservedUponExerciseOfStockOptionsOutstanding	3713	shares
CY2024Q2	EVFM	Common Stock Reserved Upon Exercise Of Common Stock Warrants CommonStockReservedUponExerciseOfCommonStockWarrants	10598201	shares
CY2024Q2	EVFM	Common Stock Capital Share Reserved For Future Issuance CommonStockCapitalShareReservedForFutureIssuance	741490642	shares
CY2024Q2	us-gaap	Convertible Preferred Stock Shares Reserved For Future Issuance ConvertiblePreferredStockSharesReservedForFutureIssuance	155468037	shares
CY2024Q2	us-gaap	Preferred Stock Capital Shares Reserved For Future Issuance PreferredStockCapitalSharesReservedForFutureIssuance	37770024	shares
CY2024Q2	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	945337558	shares

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
0001493152-24-031846-index-headers.html	Edgar Link	pending
0001493152-24-031846-index.html	Edgar Link	pending
0001493152-24-031846.txt	Edgar Link	pending
0001493152-24-031846-xbrl.zip	Edgar Link	pending
evfm-20240630.xsd	Edgar Link	pending
ex10-5.htm	Edgar Link	pending
ex10-6.htm	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
evfm-20240630_cal.xml	Edgar Link	unprocessable
evfm-20240630_def.xml	Edgar Link	unprocessable
evfm-20240630_lab.xml	Edgar Link	unprocessable
evfm-20240630_pre.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
form10-q_htm.xml	Edgar Link	completed
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$EVFM
Evofem Biosciences, Inc. Stock $evfm

2024 Q3 Form 10-Q Financial Statement

#000149315224031846 Filed on August 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EVFM Evofem Biosciences, Inc. Stock $evfm

2024 Q3 Form 10-Q Financial Statement

#000149315224031846 Filed on August 14, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EVFM
Evofem Biosciences, Inc. Stock $evfm